SEC Form 4 · accession 0001203311-17-000006
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2017 | M | 4,042 | $10.20 | A | 640,477 | D | |
| Common StockF2,F3 | Feb 6, 2017 | S | 4,042 | $61.13 | D | 636,435 | D | |
| Common Stock | Feb 6, 2017 | M | 10,323 | $10.29 | A | 646,758 | D | |
| Common StockF4,F3 | Feb 6, 2017 | S | 10,323 | $61.69 | D | 636,435 | D | |
| Common Stock | Feb 6, 2017 | M | 100 | $10.29 | A | 636,535 | D | |
| Common StockF3 | Feb 6, 2017 | S | 100 | $62.51 | D | 636,435 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $10.20 | Feb 6, 2017 | M | 4,042 | D | — | May 25, 2017 | Common Stock | 4,042 | 12,123 | D |
| Non-Qualified Stock Option (right to buy)F6 | $10.29 | Feb 6, 2017 | M | 10,323 | D | — | Aug 28, 2017 | Common Stock | 10,323 | 62,628 | D |
| Non-Qualified Stock Option (right to buy)F6 | $10.29 | Feb 6, 2017 | M | 100 | D | — | Aug 28, 2017 | Common Stock | 100 | 62,528 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $60.56 to $61.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $61.44 to $62.35. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.
- F6Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares are fully vested on 8/28/11.